Curezma is an Australian dermatology-focused biotech developing a portfolio of technologies targeting inflammatory skin conditions.

We have developed Australia’s first patented, steroid-free & clinically proven topical technology for atopic dermatitis (eczema).

Our topical eczema care products are listed with Therapeutic Goods Administration (TGA), Australia and paediatrician & dermatologist approved.

Curezma successfully went through one of the largest clinical trials to ensure the safety & efficacy of our products. Our clinically proven eczema range delivers barrier repair and flare-up control without steroids

In pre-clinical development, we are advancing the world's first Oral Dissolving Film (ODF) for moderate AD , providing IgE and histamine control without immune suppression.

Our pipeline extends further into Rosacea, Acne, and Psoriasis. With patented IP, a growing clinical evidence base, and a scalable multi-condition platform, Curezma is positioned to redefine the standard of care in dermatology therapeutics.

Why work with us

Curezma has developed the world's first dual-axis therapeutic approach for atopic dermatitis by combining a patented, topical technology that targets inflammation, restores the skin barrier with a first-in-class ODF that targets IgE and histamine control without immune suppression.

With a TGA listed product range already generating clinical outcomes, a pre-clinical ODF program advancing rapidly, and a pipeline extending into Psoriasis, Rosacea, and Acne, Curezma represents a rare convergence of proven science, unmet need, and scalable platform technology. Whether you are a clinician seeking better options for your patients, a research partner looking to advance the frontier of inflammatory skin disease, or an investor seeking an early position in a credible dermatology platform — Curezma offers a compelling and differentiated opportunity to be part of redefining the standard of care in dermatology.